Abstract: Objective To investigate the clinical efficacy of Meropenem combined with Levofloxacin in patients with severe septic shock. Methods 100 patients with severe septic shock from January 2021 to June 2022 in Enshi City Central Hospital were selected as research objects, according to the treatment of all severe septic shock patients were divided into observation group (n=47) and control group (n=53). All patients were given nutritional support, water-electrolyte balance, and anti-infection. The control group received intravenous drip of Meropenem on the basis of conventional treatment, and the observation group received intravenous drip of Meropenem combined with Levofloxacin on the basis of conventional treatment. The clinical efficacy, levels of inflammatory factors, levels of blood urea nitrogen (BUN), serum creatinine (Scr), alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate, creatine kinase (CK) and adverse reactions of the two groups were compared. Results The total effective rate of observation group was significantly higher than that of control group (P<0.05). After treatment, the levels of C-reactive protein (CRP), procalcitonin (PCT) and WBC count-related inflammatory factors in the control group were decreased, and the observation group was significantly lower than the control group (P<0.05). After treatment, BUN, Scr, ALT, AST, lactic acid and CK levels were decreased, and observation group was significantly lower than control group (P<0.05). After treatment, the values of CD4⁺, CD3⁺ and CD4⁺/ CD8⁺ in both groups were increased, and the observation group was higher than the control group (P<0.05). ConclusionMeropenem combined with Levofloxacin in the treatment of severe septic shock patients can reduce the clinical symptoms of patients, improve the therapeutic effect, reduce the level of inflammatory factors, reduce the damage caused by shock to the kidney function, heart function and liver function of patients, reduce the severity of shock, and improve the immune function of patients.

Key words: meropenem, levofloxacin, severe sepsis, shock, inflammatory factor